Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14: Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
08/07/2014 > 238 patent applications in 180 patent subcategories.

20140221270 - Methoxypolyethyleneglycol succinimidyl propionate modified recombinant ganoderma immunoregulatory protein, preparing method and application thereof: Methoxypolyethyleneglycol succinimidyl propionate modified recombinant ganoderma immunoregulatory protein, a preparing method and applications thereof are provided, including: the mPEG-SPA modified rLZ-8; the method for preparing the mPEG-SPA modified rLZ-8 comprising: feeding the rLZ-8 dimer and the mPEG-SPA with the molar ratio of 1:1˜1:6 into a 0.1M phosphate buffer with pH... Agent:

20140221271 - Shk-based pharmaceutical compositions and methods of manufacturing and using the same: Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO: 1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide... Agent: Kineta One, LLC

20140221272 - Reconstituted hdl formulation: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.... Agent:

20140221273 - Anti-microbial peptides and methods of use thereof: The present disclosure provides antimicrobial peptides, and compositions comprising same. The present disclosure further provides methods of inhibiting microbial growth.... Agent: The Regents Of The University Of California

20140221274 - Low impurity content caspofungin preparation, method for preparing same, and use thereof: Disclosed is a low impurity content caspofungin pharmaceutical composition, also disclosed is a method for preparing the low impurity content caspofungin pharmaceutical composition. The caspofungin pharmaceutical composition provided in the present invention is provided with great stability.... Agent:

20140221275 - Oligopeptide for treating liver fibrosis and/or treating hepatitis b and/or improving liver function: Disclosed is an oligopeptide for treating liver fibrosis and/or hepatitis B and/or improving liver function. The oligopeptide is obtained by reflux extraction via water, ethanol precipitation and isolation through a cation exchange resin column and a gelatinous resin column from a turtle shell. Pharmaceutically conventional excipients can be added to... Agent:

20140221276 - Further novel anti-parasitic compounds: A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.... Agent: The Regents Of The University Of California

20140221277 - Method for elevating prolactin in mammals: Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also provided are methods of using certain synthetic tetrapeptide amides which are peripherally selective kappa opioid receptor agonists to elevate or stabilize serum prolactin... Agent: Cara Therapeutics, Inc.

20140221278 - Disease treatment via antimicrobial peptides or their inhibitors: Provided are methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. Also provided... Agent:

20140221279 - Regulation of energy metabolism and obesity by modulating a proliferation-inducing ligand (april) or april signaling: Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells,... Agent: Children's Hospital Medical Center

20140221281 - Dual glp1/gip or trigonal glp1/gip/glucagon agonists: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.... Agent: Sanofi

20140221280 - Novel compounds and their effects on feeding behaviour: Peptide containing sequence from both the GLP-1 peptide and glucagon peptide, compositions comprising said peptides and methods of using said peptides for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as obesity or diabetes, are provided... Agent: Imperial Innovations Limited

20140221283 - Glucagon/glp-1 receptor co-agonists: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.... Agent: Indiana University Research And Technology Corporation

20140221282 - Long duration dual hormone conjugates: There are provided compounds having two peptide hormones bound to a central water-soluble polymeric spacer and methods of use thereof.... Agent: Amylin Pharmaceuticals, LLC

20140221284 - Biomarkers for rapid determination of drug efficacy: The invention provides compositions and methods for determining GLP-1 analog and/or DPPIV inhibitor response in a subject. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, adiponectin, C-peptide, hsCRP, insulin, proinsulin. The simultaneous use of multiple biomarkers with independent classification... Agent: Ir2dx, Inc.

20140221285 - Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives: Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed.... Agent: Sanofi

20140221286 - Sodium channel blockers reduce glucagon secretion: It is discovered that sodium-channel blockers inhibit the secretion of glucagon from pancreatic alpha cells. The present disclosure, based on such discoveries, provides compositions and methods for the treatment of hyperglycemia and related diseases and conditions with Na-channel blockers.... Agent:

20140221287 - Amylin peptides and derivatives and uses thereof: There are provided polypeptide conjugates having enhanced duration of biological activity, and methods of use thereof. The polypeptide conjugates include duration enhancing moieties, including water soluble polymers, bound to the polypeptide components of defined sequence. Methods of use are provided for treatment of metabolic disorders. Methods of use are provided... Agent: Amylin Pharmaceuticals, LLC

20140221288 - Methods for rapidly treating severe hypoglycemia: Disclosed is a method for treating or preventing hypoglycemia in a patient comprising administering an effective amount of a composition comprising a glucagon peptide which has been dried in a non-volatile buffer, and wherein the glucagon peptide has a pH memory that is about equal to the pH of the... Agent:

20140221289 - Thixotropic a-lactalbumin hydrogels, method for preparing same and uses thereof: The present invention relates to shear-thinning α-lactalbumin hydrogels, which have a threshold and are thixotropic, to a method for preparing same and to the use thereof.... Agent: Centre National De La Recherche Scientifique

20140221290 - Stabilizing agent for pharmaceutical proteins: A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.... Agent: Octapharma Ag

20140221291 - Compositions and methods for modulating thrombin generation: Factor V peptides and methods of use thereof are disclosed.... Agent:

20140221292 - Polyionic dendrimer and hydrogel comprising same: Provided is a hydrogel which comprises water as the main component at a high water content and has mechanical strength suitable for practical use and which exhibits high transparency and self-healing and shape-retaining properties. Also provided are both a material for the hydrogel and a novel polyionic dendrimer. A polyionic... Agent: Japan Science And Technology Agency

20140221293 - Fish protein hydrolysate having a bone-stimulating and maintaining activity, nutraceutical and pharmacological compositions comprising such a hydrolysate and method for obtaining same: The present invention relates to a fish protein hydrolysate having a biological activity of interest, in particular an effect on the stimulation and maintenance of bone. The fish protein hydrolysate is characterized in that it is obtained by enzymatic hydrolysis of at least one protein source selected from the fish... Agent: Compagnie Des Peches Saint Malo Sante

20140221294 - Sulphated hyaluronic acid for treating degenerative osteoarthritis: This invention relates to oral and intra-articular formulations based on sulphated hyaluronic acid which are effective in the treatment of degenerative osteoarthritis.... Agent:

20140221295 - Modified binding proteins inhibiting the vegf-a receptor interaction: The present invention relates to binding proteins specific for Vascular Endothelial Growth Factor A (VEGF-A), in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx (wherein xxx denotes the amino acid length of the VEGF-A mature protein) binding to Vascular Endothelial Growth... Agent: Molecular Partners Ag

20140221296 - Methods of phosvitin extraction and phosphopeptide preparation from egg yolk: The invention is directed to methods for extracting phosvitin from egg yolk involving contacting the egg yolk or egg yolk protein granules with a solution having a salt concentration of about 10% to form a mixture; optionally, heating the mixture; adjusting the pH of the mixture to separate phosvitin from... Agent: The Governors Of The University Of Alberta

20140221297 - Topical antiviral formulations: The disclosure provides antiviral pharmaceutical compositions comprising one or more antiviral compounds and 2-deoxy-D-glucose in the form of lip-balms, creams and ointments. A specific embodiment discloses a lip-balm composition comprising acyclovir and 2-deoxy-D-glucose.... Agent: 3b Pharmaceuticals, Inc.

20140221298 - Agricultural and horticultural fungicidal composition: in the formula (1), X each independently represents a halogeno group or a C1 to 6 alkyl group; n represents the number of X(s) and is an integer of 0 to 6; and X′ represents a halogeno group; and R1, R2 and R3 each independently represent a C1 to 6... Agent:

20140221299 - Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation: This invention relates to a veterinary antiparasitic solubilised composition including a macrocyclic lactone or a pharmaceutically equivalent salt thereof, and levamisole or a pharmaceutically equivalent salt thereof, characterised in that the pH of the composition is in the range of 2.0 to 5.0 and wherein the composition includes at least... Agent: Bayer New Zealand Limited

20140221300 - Use of macrolides in pest control: In an embodiment the present invention is drawn to a a method of controlling wood pests and molluscs with a macrolide compound, wherein a pesticidally active amount of a pesticide comprising, as pesticidally active compound, at least one macrolide, in free form or agrochemically utilizable salt form, as active ingredient... Agent: Syngenta Participations Ag

20140221301 - Combination treatment for cancer: A method of treating a cancer comprising administering to a subject in need thereof an effective amount of a glycylcycline, for example tigecycline in combination with a chemotherapeutic such as daunorubicin or cytarabine.... Agent:

20140221302 - Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis: The present invention is antibiotic compositions, ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist... Agent: Cardeas Pharma, Inc.

20140221303 - Hydraulic cements, methods and products: Non-aqueous hydraulic cement compositions comprise a non-aqueous mixture of a powder composition and a non-aqueous water-miscible liquid. In one embodiment, powder composition is a Brushite or Monetite-forming calcium phosphate powder composition. In another embodiment, the powder composition comprises porous β-tricalcium phosphate (β-TCP) granules and at least one additional calcium phosphate... Agent: Ossdsign Ab

20140221457 - Ameliorating oxidative stress in neurodegenerative disease via nox1 targeting: Disclosed herein are methods, compounds and compositions designed for ameliorating oxidative stress in cells. In particular, disclosed are viral vectors that express RNA interfering molecules for inhibiting expression or activity of Nox1 or RAC1. Depending on the location of administration, expression of inhibiting molecules can reduce oxidative stress in neurons... Agent: University Of Central Florida Research Foundation, Inc.

20140221459 - Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.... Agent: Engeneic Molecular Delivery Pty Ltd.

20140221455 - Differentiation modulating agents and uses therefor: The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including,... Agent: Verva Pharmaceuticals, Inc.

20140221454 - Extended dicer substrate agents and methods for the specific inhibition of gene expression: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a pattern... Agent: Dicerna Pharmaceuticals, Inc.

20140221460 - Method for identifying modulators of hcv translation or replication involving the ns5b polypeptide and a pseudoknot: The invention relates to a method for identifying compounds that act as modulators of hepatitis C (HCV) translation and/or replication, and to compounds identified by this method, and their uses in medicine. The invention also relates to an RNA useful for identifying modulators of HCV translation and/or replication. The invention... Agent: The University Of Warwick

20140221458 - Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolate muscle cell with a molecule that binds to a continuous stretch of at least 21... Agent: Prosensa B.v.

20140221461 - Nucleic acid molecules and uses thereof: Provided in this application are formulations of double stranded RNA molecules and Krebs Cycle analogs that improving ribonuclease stability, reducing off-target effects of a double stranded siRNA molecule, or of reducing interferon responsiveness of a double stranded siRNA molecule using such dsRNA. Also disclosed are methods of treating a primary... Agent: Atossa Genetics, Inc.

20140221456 - Targeting p63 to re-activate dormant reserve stem cells in olfactory epithelium: Disclosed herein is a method for activating a dormant epithelial stem cell, or population thereof, to a state of multipotency comprising, reducing the level of ΔNp63 in the cell(s). The dormant epithelial stem cell(s) may be a horizontal basal cell (HBC) of the olfactory epithelium and the level of ΔNp63... Agent: Trustees Of Tufts College

20140221464 - Compositions and methods for treating skeletal myopathy: The present invention provides a method of preventing or treating a myopathy, such as a skeletal myopathy, comprising administering a modulator of a miRNA. In one embodiment, the skeletal myopathy is centronuclear myopathy. The modulator can be an agonist that promotes the expression, function or activity of a miR-133 family... Agent: Board Of Regents, The University Of Texas System

20140221462 - Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia: A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy... Agent: Cnrs (centre National De La Recherche Scientifique)

20140221463 - Methods for heart regeneration: Methods for heart regeneration are provided. The invention provided herein includes methods of modulating proliferation of cardiomyocytes using small molecules and micro RNAs. In embodiments, the methods provided may be used to increase proliferation or cardiomyocytes. Further provided are methods to be used for the treatment of myocardial infarction.... Agent: The Salk Institute For Biological Studies

20140221466 - Microrna inhibitors: The present invention relates to microRNAs (miRNAs) that are associated with obesity. The present invention is directed to methods, compounds, and compositions for preventing and treating obesity, as well as related diseases, using a microRNA inhibitor.... Agent: Ottawa Hospital Research Institute

20140221465 - Modified polynucleotides for treating galactosylceramidase protein deficiency: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.... Agent: Moderna Therapeutics, Inc.

20140221304 - 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases: The present invention relates to 5′-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, R1, R2, R3 and R3′ are as defined herein. The present invention also relates to compositions comprising at least one 5′-Substituted Nucleoside Analog, and methods of using the 5′-Substituted Nucleoside... Agent:

20140221305 - Compositions and methods for treating cancer: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.... Agent: Eisai Inc.

20140221306 - Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate: Regarding Diquafosol ophthalmic solution comprising a chelating agent, formation of insoluble precipitates found in Diquafosol ophthalmic solution during its storage, as well as deterioration of the filtration performance in the course of production (filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, enhancement of preservative... Agent: Santen Pharmaceutical Co. Ltd

20140221307 - In-situ gel forming compositions: The present application provides rapid-gelling, sprayable hyaluronic-acid based compositions, kits, related methods, precursor formulations, and uses thereof.... Agent:

20140221308 - Methods and compositions of reducing and preventing bacterial growth and the formation of biofilm on a surface utilizing chitosan-derivative compounds: A method of treating a surface, the method comprising contacting (e.g., spraying) an effective amount of a composition comprising a chitosan (e.g., soluble or derivatized chitosan) with the surface, thereby treating the surface. Non-pharmaceutical compositions (e.g., liquid or dry powder compositions) include chitosan (e.g., a soluble or derivatized chitosan). The... Agent: Synedgen, Inc.

20140221309 - Eye drop formulation with enhanced properties by combining sodium hyaluronate with carboxymethylcellulose: Embodiments described herein relate to formulations for and methods of use for eye drop formulations comprising carboxymethyl cellulose (CMC) and hyaluronic acid (HA) with an improved distribution on the cornea during blinking.... Agent: Allergan, Inc.

20140221310 - Flap modulators: b

20140221311 - Flap modulators: or a form thereof, wherein ring A, R1, R2, R3, R3′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope... Agent: Janssen Pharmaceutica Nv

20140221313 - A new classifier for the molecular classification of multiple myeloma: The present invention is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The invention also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well... Agent: Erasmus University Medical Center Rotterdam

20140221312 - Use of benzoxaboroles as volatile antimicrobial agents on meats, plants, or plant parts: This invention is related to use of a volatile antimicrobial compound against pathogens affecting meats, plants, or plant parts. The volatile antimicrobial compounds provided include certain oxaborole compounds, for example benzoxaboroles. Delivery systems are provided to take advantage of the volatile nature of these antimicrobial compounds. Also combinations with a... Agent: Dow Agrosciences LLC

20140221314 - Tricyclic inhibitors of poly(adp-ribose)polymerase: The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with... Agent: Newgen Therapeutics, Inc.

20140221315 - Pyrimido-pyridazinone compounds and methods of use thereof: The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R1 and R2... Agent: Endo Pharmaceuticals Inc.

20140221316 - No- and h2s- releasing compounds: This disclosure relates to novel compounds containing an H2S releasing moiety and a nitric oxide (NO) releasing moiety covalently linked with a core (e.g., a salicylic acid moiety) and the use of such compounds in treating inflammatory diseases, including cancers. Therapeutic potency of these compounds is significantly higher than NSAIDs... Agent: Research Foundation Of The City University Of New York

20140221317 - Novel compounds as receptor modulators with therapeutic utility: The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20140221318 - Biocidal compositions and methods of use: Provided are biocidal compositions comprising: a hydroxymethyl-substituted phosphorus compound and a polymeric biguanide. The compositions are useful for controlling microorganisms in aqueous or water-containing systems.... Agent:

20140221319 - Small molecule cd38 inhibitors and methods of using same: The invention provides methods and compositions for inhibiting CD 38 activity, and methods of treating or preventing various disorders associated with CD38 activity.... Agent: President And Fellows Of Harvard College

20140221320 - Topical minocycline ointment for suppression of allergic skin responses: The method of the present application is directed towards a method for suppressing an allergic response in response to an allergic trigger. This method comprises the following steps; applying, topically, to an affected area an effective amount of a minocycline composition so that the minocycline composition contacts the affected area... Agent: The Research Foundation For The State University Of New York

20140221321 - Compositions and methods for the treatment of neurodegenerative and other diseases: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.... Agent: Glialogix, Inc.

20140221322 - Heteroaryl substituted urea modulators of fatty acid amide hydrolase: Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating... Agent: Janssen Pharmaceutica Nv

20140221323 - Fatty acid acetylated salicylates and their uses: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.... Agent: Catabasis Pharmaceuticals, Inc.

20140221324 - Composition for the reduction of drip losses in pork: 25-hydroxyvitamin D3 has been found to reduce drip losses in swine carcasses. Feed containing about 25-75 μg/kg 25-hydroxyvitamin D3 improves the water holding capacity of meats, including pork.... Agent: DsmIPAssets B.v.

20140221325 - Glomerulonephritis biomarkers: The present invention relates to methods of diagnosing glomerulonephritis (GN) in a patient, as well as methods of monitoring the progression of GN and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the... Agent: Meso Scale Technologies, LLC

20140221326 - Ophthalmologic irrigation solutions and method: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing... Agent: Omeros Corporation

20140221327 - Method of diagnosing and therapeutically treating a patient for a traumatic brain injury: Known or suspected traumatic brain injuries may be treated therapeutically by administering a therapeutically effective dose of resibufogenin. A preferred method for determining if a patient has a traumatic brain injury includes obtaining a body specimen from the patient, determining the concentration of marinobufagenin in the body specimen, comparing the... Agent:

20140221328 - Pharmaceutically acceptable salts of novel betulinic acid derivatives: The present invention relates to certain novel salts of Betulinic acid derivatives, to process for preparing such compounds, to use the compounds in treating diseases or disorders mediated by HIV infection, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent:

20140221329 - Novel estrogen receptor mutations and uses thereof: Novel mutant ESR1 molecules and uses are disclosed.... Agent: Foundation Medicine, Inc.

20140221330 - Ndm inhibitor: An objective of the present invention is to provide a novel NDM (New Delhi metallo-β-lactamase) inhibitor that functions as a drug for restoring the antibacterial activity of β-lactam antibiotics that have been inactivated as a result of decomposition by NDM. According to the present invention, there is provided an NDM... Agent:

20140221331 - Regulation of nitric oxide release and biofilm development: The present invention relates generally to methods and compounds for regulating the release of nitric oxide in the vicinity of biofilm-forming microorganisms to regulate programmed cell death in the microorganisms and thereby promote dispersal of microorganism from biofilms and/or inhibit biofilm formation or development. More particularly, the invention relates to... Agent: Newsouth Innovations Pty Limited

20140221333 - Btk inhibitors: Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.... Agent:

20140221341 - Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors: o

20140221340 - Chemokine receptor activity regulator:

20140221336 - Compounds useful as inhibitors of janus kinases: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Incorporated

20140221339 - Heterocyclic derivative and pharmaceutical drug: wherein R1 and R2 are the same or different aromatic rings, etc., and ring A is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mPGES-1 inhibiting activity and is useful as an agent for the treatment or prevention of a disease, such... Agent: Nippon Shinyaku Co., Ltd.

20140221338 - Novel macrocycles as factor xia inhibitors: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising... Agent: Bristol-myers Squibb Company

20140221337 - Potassium channel blockers: e

20140221335 - Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity: and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological... Agent: Boehringer Ingelheim International Gmbh

20140221342 - 6-substituted phenoxychroman carboxylic acid derivatives: d

20140221334 - Kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20140221332 - Metabotrophic glutamate receptor 5 modulators and methods of use thereof: Compounds that modulate GluR5 activity and methods of using the same are disclosed.... Agent: Sunovion Pharmaceuticals Inc.

20140221344 - Bicyclic pyridazine compounds as pim inhibitors: The invention relates to bicyclic compounds of formulas I and I′, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein,... Agent:

20140221343 - Fused amino pyridine as hsp90 inhibitors: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.... Agent: Curis, Inc.

20140221348 - Novel bicyclic antibiotics: e

20140221345 - Prmt5 inhibitors and uses thereof: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.... Agent: Epizyme, Inc.

20140221346 - Therapeutic compounds: s

20140221347 - Therapeutic compounds:

20140221349 - Indanyloxydihydrobenzofuranylacetic acids: wherein the group R1 is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes... Agent: Boehringer Ingelheim International Gmbh

20140221350 - Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists: The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male... Agent: Hoffmann-la Roche Inc.

20140221352 - Compositions and methods for inhibition of the jak pathway: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.... Agent: Rigel Pharmaceuticals, Inc.

20140221351 - Novel 1,2- bis-sulfonamide derivatives as chemokine receptor modulators: The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.... Agent: Allergan, Inc.

20140221353 - Methods for determining the oncogenic condition of cell, uses thereof, and methods for treating cancer: The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale)

20140221354 - Imidazo [1,2-a]pyridine compounds for use in therapy: The present invention provides novel imidazo[1,2-a]pyridine compounds that are useful in therapy of diseases and disorders. The novel compounds inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspect, the compounds of the present invention are useful for the preparation of a medicament... Agent: Emblem Technology Transfer Gmbh

20140221355 - Polycyclic-carbamoylpyridone compounds and their pharmaceutical use: e

20140221356 - Polycyclic-carbamoylpyridone compounds and their pharmaceutical use:

20140221357 - Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors: The present invention provides compounds of Formula (I) or Formula (III): [INSERT CHEMICAL STRUCTURE HERE] (I) [INSERT CHEMICAL STRUCTURE HERE] (III) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.... Agent: Bristol-myers Squibb Company

20140221358 - Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.... Agent: Amarin Pharmaceuticals Ireland Limited

20140221359 - 3,7-diamino-10h-phenothiazine salts and their use: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is... Agent: Wis Ta Laboratories Ltd.

20140221360 - Use of aminodihydrothiazines for the treatment or prevention of diabetes: e

20140221361 - C-19 modified triterpenoids with hiv maturation inhibitory activity:

20140221363 - Composition and method for controlling harmful arthropods: The present invention provides a composition for controlling harmful arthropods having an excellent control efficacy on harmful arthropods. A composition for controlling harmful arthropods comprising an amide compound represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof, and at... Agent: Sumitomo Chemical Company, Limited

20140221362 - Heterocyclic compounds as pesticides: The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation.... Agent: Bayer Cropscience Ag

20140221365 - Alkylated piperazine compounds: Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating cancer mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of cancer in... Agent: Genentech, Inc.

20140221364 - Tetrahydroquinoline analogues as muscarinic agonists: The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment... Agent: Acadia Pharmaceuticals, Inc.

20140221366 - Substituted azaheterocycles for the treatment of cancer: The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.... Agent: Merck Patent Gmbh

20140221367 - Pharmaceutical compounds: Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate.... Agent: F. Hoffmann-la Roche Ag

20140221369 - 5-deutero-2,4-thiazolidinedione and 5-deutero-2,4-oxazolidinedione derivatives and compositions comprising and methods of using the same: The invention provides 5-deuterium enriched 2,4-thiazolidinediones and 2,4-oxazolidinediones, such as 5-(4-((6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzo[d]imidazol-2-yl)methoxy)benzyl)-5-deutero-thiazolidine-2,4-dione, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treating medical disorders, such as cancer, using the same.... Agent: Deuterx, LLC

20140221368 - Biomarkers of therapeutic responsiveness: The present invention relates to methods of diagnosing breast cancer in a patient, as well as methods of monitoring the progression of breast cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with... Agent: Meso Scale Technologies, LLC

20140221370 - Pyrrolopyridines as kinase inhibitors: Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.... Agent: Array Biopharma Inc.

20140221371 - Heterocyclic compounds and their use as binding partners for 5-ht5 receptors: The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are... Agent:

20140221372 - Method of administration and treatment: if said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and/or the TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene, administering to said patient a pharmaceutical composition comprising foretinib or a pharmaceutically acceptable salt thereof.... Agent: Glaxosmithkline Intellectual Property (no 2.) Limited

20140221373 - Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase: The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A1, A2, A3, L1, L2 and D are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also... Agent: Boehringer Ingelheim International Gmbh

20140221374 - Raf kinase inhibitors: Described herein are compounds, pharmaceutical compositions and methods for the inhibition of RAF kinase mediated signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human disease and disorders.... Agent: Ruga Corporation

20140221375 - Method for treating proliferative disorders associated with mutations in c-met: The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating c-Met associated cancers, in a subject in need thereof.... Agent: Synta Pharmaceuticals Corp.

20140221376 - Substituted pyridazine carboxamide compounds as kinase inhibitor compounds: Pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.... Agent: Xcovery Holding Company, LLC

20140221377 - Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.... Agent:

20140221379 - N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors: e

20140221378 - Substituted spiropyrido[1,2-a]pyrazine derivative and pharmaceutical use of same as hiv integrase inhibitor:

20140221380 - Substituted spiropyrido[1,2-a]pyrazine derivative and pharmaceutical use of same as hiv integrase inhibitor:

20140221381 - Thienopyrimidine compounds and use thereof: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a hydroxy group, (3′) a C1-4 alkyl and (4′) a C1-4 alkoxy, (2) a phenyl which may have a... Agent: Takeda Pharmaceutical Company Limited

20140221382 - Viral inhibitors: e

20140221383 - Cetp inhibitors: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring... Agent: Merck Sharp & Dohme Corp.

20140221384 - Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaecutical use: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular,... Agent: Erimos Pharmaceuticals LLC

20140221385 - Combinations of serotonin receptor agonists for treatment of movement disorders: The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1... Agent: Concit Pharma Aps

20140221386 - Combinations of akt inhibitor compounds and erlotinib, and methods of use: The invention provides A combination of a) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.... Agent: Genentech, Inc.

20140221387 - Compositions and methods useful for treating diseases: The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers,... Agent: Eutropics Pharmaceuticals, Inc.

20140221388 - Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram,... Agent: Otsuka Pharmaceutical Co., Ltd.

20140221389 - Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients: The present invention relates to a method of treating a cancer in patient in need thereof by administering 4-amino-5 fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one, or a tautomer thereof, or a salt of any one of them, wherein the patient is a moderate hepatic impaired patient.... Agent: Novartis Ag

20140221390 - Prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis: Provided is a compound useful in the prevention and treatment of non-alcoholic steatohepatitis. A prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis which contains, as the active ingredient, 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an acid-addition salt thereof, or a solvate of the same.... Agent: Kowa Company, Ltd.

20140221391 - Cyclohexane derivative compound: To find a therapeutic and/or prophylactic agent for gastrointestinal disorders and so on, the agent having excellent activity and high safety. A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents an optionally substituted phenylene group; B represents an optionally... Agent: Daiichi Sankyo Company, Limited

20140221392 - Cyclohexane derivative compound: To find a therapeutic and/or prophylactic agent for gastrointestinal disorders and so on, the agent having excellent activity and high safety. A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents an optionally substituted phenylene group; B represents an optionally... Agent: Daiichi Sankyo Company, Limited

20140221393 - Itraconazole analogs and use thereof: Provided herein are Itraconazole analogs. Also provided herein are methods of inhibition of Hedgehog pathway, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, angiogenesis and treatment of disease with Itraconazole analogs.... Agent: The Johns Hopkins University

20140221394 - Hydrobenzamide derivatives as inhibitors of hsp90: The invention provides an acid addition salt of a compound of the formula (1). Also provided by the invention are processes for preparing the compound of formula (1) and alkyl analogues thereof, novel intermediates for use in the process and methods for preparing the intermediates. The invention also provides new... Agent: Astex Therapeutic Ltd.

20140221395 - Deuterium-enriched alkyl sulfonamides and uses thereof: The present invention is concerned with deuterium-enriched sulfonamides of formula 1, their pharmaceutically acceptable salts and methods of use thereof for the treatment of anxiety disorders including, General Anxiety Disorder (GAD), Panic Disorder (PD), Post-Traumatic Stress Disorder (PTSD), Social Phobia (SP), Health Anxiety (Hypochondriasis), depression, major depressive disorders, unipolar depression,... Agent:

20140221396 - Tubulin inhibitors: Compounds of general formula (I), (II), (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II),... Agent: Ym Biosciences Australia Pty Ltd.

20140221397 - Fibrosis inhibitor: m

20140221398 - Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors: The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as... Agent: Principia Biopharma Inc.

20140221400 - Use of myeloperoxidase (mpo) inhibitors or pharmaceutically acceptable salts thereof to treat multiple sysyem atrophy (msa) 938: The present invention relates to the use of MPO inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection.... Agent: Astrazeneca Ab

20140221401 - Methods and compositions for treating pain: The present application relates to compounds and methods for treating pain, incontinence and other conditions.... Agent: Hydra Biosciences, Inc.

20140221399 - Method of treating functional somatic syndromes with combination of famciclovir and celecoxib: The present invention relates to methods of treating fibromyalgia by administering a therapeutically-effective combination-dosage of famciclovir and celecoxib. The invention is also related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination-dosage of famciclovir and celecoxib.... Agent: Innovative Med Concepts, LLC

20140221402 - Quinazoline derivative and application thereof: wherein: each of R1 and R2 independently, is selected from H, C1-C6 alkoxy, halo-C1-C6 alkoxy, C1-C6-alkoxy-C1-C6 alkoxy, C3-C8 cycloalkoxy, C3-C8 heterocycloalkoxy containing at least one of heteroatoms selected from N, O, S; Z is —NR4—, C(R5)2, S or —O—, wherein R4 is H or C1-C3 alkyl, R5 is the same... Agent: Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences

20140221403 - Quinazoline based egfr inhibitors containing a zinc binding moiety: e

20140221404 - Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene: In order to identify a gene that can serve as an indicator for predicting the effectiveness of a drug treatment of cancer and to provide a novel method for predicting the effectiveness of a drug treatment targeting said gene, lung adenocarcinomas were subjected to whole-transcriptome sequencing. As a result, in-frame... Agent: National Cancer Center

20140221405 - Platelet adp receptor inhibitors: Novel compounds of formulae (I) to (VII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylfulfonamide derivatives which are effective platelet ADF receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of... Agent: Portola Pharmaceuticals, Inc.

20140221406 - Quinazoline-7-ether compounds and methods of use: The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline... Agent: Newgen Therapeutics, Inc.

20140221407 - Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies: Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for the treatment of facial wrinkling are provided.... Agent: Phytotox Limited

20140221408 - Pesticidal pyrimidine compounds: Pyrimidine compounds and their use in controlling pests such as insects and other invertebrates are provided. Further embodiments, forms, objects, features, advantages, aspects and benefits shall become apparent from the description.... Agent: Dow Agrosciences, LLC

20140221410 - Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives: The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.... Agent: Scifluor Life Sciences, LLC

20140221409 - Nitrogen-containing six-membered aromatic ring derivatives and pharmaceutical products containing the same: in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, an amino group or the like; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the... Agent: Daiichi Sankyo Company, Limited

20140221411 - 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient: The present invention relates to a 2-hydroxyarylamide derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient. The 2-hydroxyarylamide derivative prepared by the present invention is excellent in the inhibition of the activity... Agent: Korea Research Institute Of Bioscience And Biotechnology

20140221412 - Therapeutic compounds and methods: The invention provides compounds of formula I: and salts thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating cancer using compounds of formula I.... Agent: Department Of Veterans Affairs

20140221413 - Preoperative treatment of post operative pain: A method of treating postoperative pain in a patient undergoing a surgery is described. The method is based on preoperative administration of a buprenorphine-containing transdermal dosage form. The dosage form can be administered to the patient, for example, 1-4 days prior to surgery. Alternative embodiments of the invention include subsequent... Agent: Purdue Pharma L.p.

20140221414 - Solid dispersion of rifaximin: A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin.... Agent: Lupin Limited

20140221415 - Method of treating dyskinesia: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor... Agent: Rutgers, The State University Of New Jersey

20140221416 - Tamper resistant pharmaceutical formulations: Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.... Agent: Purdue Pharma L.p.

20140221417 - Therapeutic compounds: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.... Agent: Gilead Sciences, Inc.

20140221418 - Hyaluronic acid based copolymers: Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and... Agent: Abbott Cardiovascular Systems Inc.

20140221419 - Benzomorphan analogs and the use thereof: a

20140221420 - Ccr5 antagonists for treating hiv: Compounds that modulate the CCR5 chemokine receptor, pharmaceutical compositions containing them, and uses therefor in the treatment of HIV and related diseases are described.... Agent: Purdue Research Foundation

20140221421 - Therapeutic compounds: m

20140221422 - Novel thienopyridine compounds, and methods of use thereof: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).... Agent: Fibrogen, Inc.

20140221423 - Agents and methods for treating ischemic and other diseases: This invention relates to compounds that modulate TRPM7 protein activity and use of the same for treatment or prophylaxis of ischemia, cancer, pain or glaucoma.... Agent:

20140221424 - Pharmaceutical compositions for use in the treatment of cystic fibrosis: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and pharmaceutical compositions thereof for the treatment of cystic fibrosis, in patients, including kits and/or products thereof.... Agent:

20140221425 - Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof: Provided in the present invention is a quinolyl-containing hydroxamic acid compound as shown in formula (I), at the same time also disclosed is the preparation method of the compound and the use thereof, and a pharmaceutical composition containing the quinolyl-containing hydroxamic acid compound. Such compounds are inhibitors of protein kinases... Agent: Beijing Konruns Pharmaceutical Co., Ltd.

20140221426 - Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactivities: Presystemic metabolism in intestine of bioactives such as phenylephrine is avoided by administering a subject (human or animal) the bioactive (e.g., phenylephrine) in combination with one or more inhibitors of sulfation (e.g., sulfotransferase enzymes aka SULTs). This can also be enhanced be co-administering inhibitors of monoamine oxidases aka, MAOs, and... Agent:

20140221427 - Isotopologues of pomalidomide: Provided herein are pomalidomide, which is enriched with isotopes such as deuterium. Pharmaceutical compositions comprising the isotopes-enriched compounds, and methods of using such compounds are also provided.... Agent: Celgene Corporation

20140221428 - Arylsulfonamide ccr3 antagonists: Provided herein are arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.... Agent: Axikin Pharmaceuticals, Inc.

20140221429 - Heterocyclic schiff's bases as novel and new antiglycation agents: The invention provides that heterocyclic Schiff bases posses protein antiglycation potential in hyperglycemia. The novel antiglycation agents 3-6 showed a moderate to potent antiglycation activity.... Agent:

20140221430 - Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid: The present invention relates to a substantially a solid form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1, Solvate Form A and Compound 1, HCl Salt Form A), processes for making such forms, pharmaceutical compositions thereof, and methods of treatment therewith.... Agent: Vertex Pharmaceuticals Incorporated

20140221431 - Novel histone deacetylase inhibitor of benzamides and use thereof: Disclosed in the present invention is a novel histone deacetylase inhibitor of benzamides and use thereof. The inhibitor has good efficacy in treating diseases caused by abnormal gene expression, such as tumours, endocrine disorders, immune system diseases, genetic diseases and nerve system diseases. The histone deacetylase inhibitor of benzamides is... Agent: Sinopharm A-think Pharmaceutical Co., Ltd

20140221432 - Composition and method for controlling harmful arthropods: The present invention provides a composition for controlling harmful arthropods having an excellent control efficacy on harmful arthropods. A composition for controlling harmful arthropods comprising an amide compound represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof and at... Agent:

20140221433 - N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate: The present invention relates to an improved and shortened synthesis of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide and the mesylate monohydrate salt thereof by using boronic acid derivatives or borolane reagents while avoiding toxic organic tin compounds and to the mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide which has demonstrated increased long term stability and release kinetics... Agent: Aicuris Gmbh & Co. Kg

20140221434 - Altering pharmacokinetics of pirfenidone therapy: The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy.... Agent: Intermune, Inc.

20140221435 - Amides as modulators of sodium channels: e

20140221436 - Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with... Agent: Ptc Therapeutics, Inc.

20140221437 - N-hetero-ring-substituted amide derivative: Compounds having an excellent hypoglycemic effect and β cell- or pancreas-preserving effects or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented... Agent: Daiichi Sankyo Company, Limited

20140221438 - Novel solid forms of epalrestat: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts... Agent: Bionevia Pharmaceuticals, Inc.

20140221439 - Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas: wherein R1 is a C10-C22 alkyl group, a C10-C22 alkenyl group having 1-6 double bonds, or a C10-C22 alkynyl group having 1-6 triple bonds; R2 and R3 are the same or different and may be chosen from different substituents; and X is a carboxylic acid or a derivative thereof, such... Agent: Pronova Biopharma Norge As

20140221440 - Composition and method for controlling plant diseases: The present invention provides a composition for controlling plant diseases having an excellent control efficacy on plant diseases. A composition for controlling plant diseases comprising a carboxylic acid compound represented by a formula (I): wherein each of symbols are the same as defined in the Description; or salts thereof and... Agent: Sumitomo Chemical Company, Limited

20140221441 - Composition and method for controlling plant diseases: The present invention provides a composition for controlling plant diseases having an excellent control efficacy on plant diseases. A composition for controlling plant diseases comprising an amide compound represented by a formula (I): wherein each of symbols are the same as defined in the Description; or salts thereof and one... Agent:

20140221442 - Use of dianhydrogalactitol and analogs and derivatives thereof to treat glioblastoma multiforme: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug... Agent: Del Mar Pharmaceuticals

20140221443 - Novel hydrogen sulfate salt: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.... Agent: Array Biopharma Inc.

20140221444 - Novel crystals and process of making 5-(-methyl)-2-methoxy-benzoic acid: The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.... Agent: Furiex Pharmaceuticals, Inc.

20140221445 - Aqueous ophthalmic solutions of phentolamine and medical uses thereof: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.... Agent: Ocularis Pharma, LLC

20140221447 - Formulation for preventing or reducing bleeding at a surgical site: An implantable drug depot useful for preventing, reducing or treating bleeding at a surgical site beneath the skin in a patient is provided. The implantable drug depot comprises a therapeutically effective amount of clonidine or a pharmaceutically acceptable salt thereof, and at least one biodegradable polymer. The drug depot is... Agent: Warsaw Orthopedic, Inc.

20140221446 - Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance: The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient... Agent: Ocularis Pharma, LLC

20140221448 - Fungicidal pyrazoles: Q1, Q2, R1, R2, R4, R5 and X are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 or Formula 1A and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of... Agent: E I Du Pont De Nemours And Company

20140221449 - Dividable galenical form allowing modified release of the active ingredient: Dividable galenical form for the modified release of active ingredient, wherein the non-subdivided galenical form and a portion of said form obtained by subdivision have identical dissolution profiles.... Agent: Les Laboratoires Servier

20140221450 - Compositions for the treatment of fragile x syndrome: The present invention relates to a composition comprising a maxi-K potassium channel opener the use in the treatment of fragile X syndrome. More specifically the present invention relates to a composition comprising a fluoro-oxindole or a chloro-oxindole for use in the treatment of fragile X syndrome.... Agent: Centre Hospitalier Regional D'orleans

20140221451 - Implants for the treatment of dopamine associated states: Biodegradable implants comprising dopamine modulating compounds are described.... Agent: Nupathe, Inc.

20140221452 - Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.... Agent: Amarin Pharmaceuticals Ireland Limited

20140221453 - D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders: The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders and the enhancement of the visual function.... Agent: Allergan, Inc.

20140221467 - Metformin derivatives for treating diabetes and diabetes complications: The invention provides mutual ternary salts of metformin, lipoic acid and acidic amino acids such as aspartic acid and glutamic acid. The invention further provides treatment of prediabetes, diabetes, diabetic complications and/or other conditions in mammals in a method that comprises administering an effective amount of one or more of... Agent:

20140221468 - Compounds that modulate store operated calcium channels: Store operated calcium channel modulating compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which modulation of store operated calcium channels is desired.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20140221469 - Phytocannabinoids for use in the treatment of cancer: The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and cell migration or metastases. Cancers, where invasion and cell migration plays a key role in prognosis include brain tumours,... Agent: Gw Pharma Limited

20140221471 - Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis: Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity... Agent:

20140221470 - Compound for inhibiting glutathione s-transferase omega 1 activity, pharmaceutical composition containing thereof, and method for synthesizing the same: in which A is p-quino, and R is selected from the group consisting of the following Formula 1a and Formula 1b, where n in Formula 1 is 1 or 2, m in Formula 1b is 1 or 2, and n′ in Formula 1b is 1, 2, or 3:... Agent: China Medical University

20140221472 - Use of myricetin or derivatives thereof as a cathepsin k inhibitor: This invention is directed to a novel inhibitor on collagen degradation caused by the activity of a human cathepsin K rising. In particular, the inhibitor is myricetin or derivatives thereof. The invention also relates to use of the novel inhibitor to manufacture a medicament in a form of pharmaceuticals, foods,... Agent:

20140221473 - Compositions, methods of use, and methods of treatment: Embodiments of the present disclosure provide compositions including ketamine analogues, salts, and disalts, pharmaceutical compositions including ketamine analogues, salts, or disalts, methods of treatment of a condition or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.... Agent:

20140221474 - Method and formulation for chemical peeling: A chemical peeling formulation and a formulation able to increase the efficacy and the tolerability of preparations based on the use of compounds used to carry out chemical peeling, comprising at least one keratolytic agent and dimethyl isosorbide. The composition may additionally comprise dimethyl sulphone.... Agent:

20140221475 - Platinum(iv) complexes and pharmaceutical composition containing the same: New platinum(IV) complexes which has a strong antitumor activity and has a feature that a side effect is relatively reduced is provided. The new complex is platinum(IV) complexes with cis,cis-spiro[4,4]nonane-1,6-diamine ligand and is platinum(IV) complexes with optically active cis,cis-spiro[4,4]nonane-1,6-diamine ligand. Especially, the new complex is dichloromalonato((1S,5S,6S)-spiro[4.4]nonane-1,6-diamine)platinum(IV).... Agent: Unitech Co., Ltd.

20140221476 - Compound, composition and uses thereof: The disclosure herein provides the compounds of Formulas 1 and its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, and/or injection. Such compositions may be used for the... Agent:

20140221477 - Process for the preparation of a sulfated derivative of 3,5-diiodo-o-[3-iodophenyl]-l-tyrosine: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure... Agent: Bracco Imaging S.p.a.

20140221478 - Di-fluoro containing compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Virobay, Inc.

20140221479 - Sarms and method of use thereof: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.... Agent: University Of Tennessee Research Foundation

20140221480 - Methods of managing brain inflammation: This disclosure relates to methods of managing brain injury such as inflammation due to trauma induced brain injury and ischemic stroke by administering resatorvid or derivative there of a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating cerebral ischemia comprising administering an effective amount... Agent: Emory University

20140221481 - Sulfur derivatives as chemokine receptor modulators: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.... Agent: Allergan, Inc.

20140221483 - Gip elevation inhibitor: A GIP-increase inhibitor, which may be utilized for producing a medicine, a food, or the like, is provided. The GIP-increase inhibitor contains triacylglycerol in which α-linolenic acid accounts for 10% by mass or more of the constituent fatty acid, as an effective ingredient.... Agent: Kao Corporation

20140221482 - Triheptanoin for the treatment of glucose transport 1 deficiency: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.... Agent: National Institute Of Health And Medical Research

20140221484 - Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention... Agent: Celera Corporation

20140221485 - Lipophilic dopamine derivatives and their use: The invention provides novel lipophilic dopamine derivatives with improved stability and physiological half-life. The compounds may be used for organ and tissue preservation during storage and transport, or in the pre-treatment of organ and tissue donor or recipients. Moreover, they may be used as therapeutic agents for the prevention or... Agent:

20140221486 - Methods of reducing apolipoprotein c-iii: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.... Agent: Amarin Pharmaceuticals Ireland Limited

20140221487 - Use of xanthophyll carotenoids to improve visual performance and neural efficiency: In one embodiment, the invention provides a method of enhancing a subject's macular pigment optical density, the method comprising administering to the subject a pharmaceutically effective amount of one or more Xanthophyll carotenoids. Preferably, the Xanthophyll carotenoids are selected from the group consisting of lutein (L), zeaxanthin (Z), and meso-zeaxanthin... Agent: University Of Georgia Research Foundation, Inc

20140221488 - Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same: The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.... Agent: Cydex Pharmaceuticals, Inc.

20140221489 - Infusion and injection solution of levodopa: A method of eliminating or significantly decreasing shifts between dyskinesia and bradykinesia in a patient suffering from an advanced stage of Parkinson's Disease comprises for a predetermined time period intravenously, subcutaneously or intrathekally administering to the patient by continuous infusion a stable and therapeutically acceptable solution comprising at least 5... Agent: Dizlin Medical Design Ab

20140221490 - Methods of treating pain: The presently disclosed subject matter is directed to methods of treating post-operative pain by administering a combination of a lower than minimum approved dose of diclofenac and beta-cyclodextrin. The presently disclosed subject matter is also directed to methods of treating pain in high risk or obese mammals in need of... Agent: Hospira, Inc.

20140221491 - In vivo method for treating, inhibiting, and/or prophylaxis of cancer, such as pancreatic cancer: An in vivo method of inhibiting tumor growth, specifically pancreatic cancer, includes administering to a subject in need thereof an effective amount of a compound, composition, and/or a pharmaceutical formulation including crocetinic acid.... Agent: University Of Kansas

20140221492 - Deuterated 2-amino-3-hydroxypropanoic acid derivatives: This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist.... Agent:

20140221493 - Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.... Agent: Allergan, Inc.

20140221494 - Medicament: e

20140221495 - Electrospun polymer nanofibers with surface active quaternary ammonium salt antimicrobials: A fiber having a polymeric matrix and a quarternary ammonium salt. The quarternary ammonium salt contains at least one aliphatic group and no aromatic groups, is not covalently incorporated into the polymeric matrix, and is present on both the surface and in the interior of the fiber. The fiber may... Agent: The Government Of The United States Of America, As Reperesented By The Secretary Of The Navy

20140221496 - Method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm: The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin,... Agent: Thomas Jefferson University

20140221497 - Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction: Methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.... Agent: Apbi Holdings, LLC.

20140221498 - Amino diol derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to amino diol derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20140221499 - Novel rodent control agents and uses thereof: Provided herein is method for controlling a rodent. The method comprises contacting the rodent with a compound which is a ligand for an olfactory trace amine associated receptor (TAAR) or a composition comprising such a molecule. The compound can be a biogenic amine.... Agent: President And Fellows Of Harvard College

20140221500 - Highly concentrated astaxanthin for topical application: A method for obtaining and topically applying a customized resulting mixture, wherein the customized resulting mixture contains astaxanthin at an individualized concentration, the method comprising: placing in a mixing place a desired amount of a highly concentrated astaxanthin composition of known astaxanthin concentration, the astaxanthin concentration being between about 0.01%... Agent:

20140221501 - Therapeutic foam: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a... Agent: Btg International Ltd.

20140221502 - Alcoholic pump foam: An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to ≦99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam... Agent: DebIPLimited

20140221503 - Novel cycloalkane aldehydes, method for preparing same, and use thereof in the perfume industry:

20140221507 - Biomarker of renal impairment: There is provided a method of determining whether a subject belongs to a first or a second group of subjects, wherein the risk of having or developing of a renal impairment is higher in the first group than in the second group, comprising the steps of: a) measuring an amount... Agent: Atlas Antibodies Ab

20140221505 - Methods and compositions for categorizing patients: The disclosure provides, among other things, molecular markers for categorizing the neoplastic state of a patient, methods for using the molecular markers in diagnostic tests, nucleic acid and amino acid sequences related to the molecular markers, reagents for detection of molecular markers, and methods for identifying candidate molecular markers in... Agent: Case Western Reserve University

20140221504 - Methods and compositions for detecting aspergillus terreus, aspergillus niger, and mycotoxins: The invention relates to a method of identifying an Aspergillus terreus or an Aspergillus niger fungal species in patient tissue or body fluid and to primers and probes for use in such a method.... Agent:

20140221506 - Methods of diagnosing neuropathic pain: The invention includes compositions and methods useful for the diagnosis, assessment, and characterization of neuropathic pain in a subject in need thereof, based upon the expression level of at least one miRNA or snoRNA that is associated with neuropathic pain.... Agent: Philadelphia Health & Education Corporation

  
  
  
Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140807: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 0.90355 seconds

PATENT INFO